MedTrace Logo

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

NCT04480736 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-01-10

No results posted yet for this study

Summary

The purpose of this study is to assess the antiviral activity of JNJ-64281802 versus placebo in terms of reduction of dengue virus 1 (DENV-1) ribonucleic acid (RNA) viral load (VL).

Conditions

  • Healthy

Interventions

DRUG

Placebo

Matching placebo will be administered orally.

DRUG

JNJ-64281802 High dose

JNJ-64281802 high dose will be administered orally.

DRUG

JNJ-64281802 Medium dose

JNJ-64281802 medium dose will be administered orally.

DRUG

JNJ-64281802 Low dose

JNJ-64281802 low dose will be administered orally.

DRUG

JNJ-64281802 Dosing Regimen X

JNJ-64281802 dosing regimen X will be administered orally.

DRUG

JNJ-64281802 Dosing Regimen Y

JNJ-64281802 dosing regimen Y will be administered orally.

DRUG

JNJ-64281802 Dosing Regimen Z

JNJ-64281802 dosing regimen Z will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-28
Primary Completion
2027-09-02
Completion
2027-12-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04480736 on ClinicalTrials.gov